In conclusion, while the research in this field has made progress, our study focuses on addressing these challenges by investigating the potential of FGF8 and ALK/EML4 pathways to provide a novel therapeutic approach to overcoming resistance in ESCC. The gene discussed is EML4; the disease is esophageal squamous cell carcinoma.